enGene's LEGEND Data Promising but Durability Lags Competitors

What happened

enGene reported preliminary Cohort 1 data from the pivotal LEGEND trial for detalimogene in high-risk BCG-unresponsive NMIBC, showing a 71% any-time complete response and 47% six-month complete response with mostly mild side effects. While these results support the path to a BLA filing, the durability falls short of Anktiva and Adstiladrin, which have demonstrated longer-term response rates. The company's $342M cash runway into 2H28 reduces near-term dilution risk, but the single-asset nature and crowded competitive field mean approval alone may not drive significant value. Current valuation near $11 already prices in a high probability of approval, leaving limited upside without proven superiority. Investors should wait for full pivotal data and regulatory clarity before committing capital.

Implication

The preliminary data is incremental but does not establish a clear competitive advantage over existing therapies. The stock's price near $11 already reflects a high probability of approval, implying limited room for error. The key uncertainty is whether detalimogene can demonstrate durability comparable to or better than Anktiva and Adstiladrin. Until longer-term data is available, the risk/reward is balanced but not compelling, warranting patience.

Thesis delta

The preliminary LEGEND data confirms the base case that detalimogene is approvable but not clearly superior, with overall CR rates within expectations but six-month CR at the lower end of competitive benchmarks. This does not materially change the thesis that ENGN is fairly valued for approval odds but lacks upside triggers for differentiation. The WAIT rating remains appropriate pending longer-term durability data.